B-ALL
MCID: BLY001
MIFTS: 52

B-Lymphoblastic Leukemia/lymphoma (B-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for B-Lymphoblastic Leukemia/lymphoma

MalaCards integrated aliases for B-Lymphoblastic Leukemia/lymphoma:

Name: B-Lymphoblastic Leukemia/lymphoma 12 15 37
B-All 12 54
Precursor B Lymphoblastic Lymphoma/leukemia 12
B Lymphoblastic Leukemia/lymphoma 6

Classifications:



External Ids:

Disease Ontology 12 DOID:0080630
NCIt 50 C8936
UMLS 71 C0862030

Summaries for B-Lymphoblastic Leukemia/lymphoma

Disease Ontology : 12 A B-cell acute lymphoblastic leukemia that is characterized by the presence of too many B-cell lymphoblasts in the blood and bone marrow.

MalaCards based summary : B-Lymphoblastic Leukemia/lymphoma, also known as b-all, is related to b-lymphoblastic leukemia/lymphoma with bcr-abl1 and b-lymphoblastic leukemia/lymphoma, bcr-abl1-like. An important gene associated with B-Lymphoblastic Leukemia/lymphoma is CD19 (CD19 Molecule), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and myeloid, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for B-Lymphoblastic Leukemia/lymphoma

Diseases in the B-Lymphoblastic Leukemia/lymphoma family:

B-Lymphoblastic Leukemia/lymphoma with T(9;22)(q34.1;q11.2) B-Lymphoblastic Leukemia/lymphoma with T
B-Lymphoblastic Leukemia/lymphoma with T(12;21)(p13.2;q22.1) B-Lymphoblastic Leukemia/lymphoma with T(1;19)(q23;p13.3)
B-Lymphoblastic Leukemia/lymphoma with T(5;14)(q31.1;q32.3)

Diseases related to B-Lymphoblastic Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 b-lymphoblastic leukemia/lymphoma with bcr-abl1 33.4 KMT2A ABL1
2 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 33.2 CDKN2A ABL1
3 b-lymphoblastic leukemia/lymphoma with hypodiploidy 33.2 TCF3 PBX1 ETV6 ABL1
4 b-lymphoblastic leukemia/lymphoma with iamp21 32.9 PBX1 PAX5 KMT2A ETV6 ABL1
5 leukemia, acute lymphoblastic 3 31.5 TCF3 PBX1 PAX5 KMT2A FLT3 ETV6
6 t-cell acute lymphoblastic leukemia 31.0 MYC IL7 FLT3 ETV6 DNTT CDKN2B
7 spindle cell sarcoma 30.7 KIT ETV6 CD34
8 leukemia 30.6 TCF3 PTPN11 PBX1 PAX5 MYC MME
9 leukemia, acute lymphoblastic 30.6 TCF3 PTPN11 PBX1 PAX5 MYC MME
10 pancytopenia 30.5 KMT2A KIT CD34 CD19 ANPEP
11 b-cell lymphoma 30.5 PAX5 MYC MME CDKN2B CDKN2A CD19
12 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.5 KMT2A KIT FLT3 ETV6 DNTT
13 lymphoma 30.4 PTPN11 PAX5 MYC KIT DNTT CDKN2B
14 lymphoblastic lymphoma 30.4 MYC MME KMT2A DNTT CDKN2B
15 myeloproliferative neoplasm 30.3 PTPN11 KMT2A KIT FLT3 ETV6 ABL1
16 myeloid leukemia 30.2 PTPN11 MYC KMT2A KIT FLT3 ETV6
17 lymphoplasmacytic lymphoma 30.2 PAX5 MME CD19
18 severe combined immunodeficiency 30.1 KIT IL7 FLT3 CD34 CD19
19 mental retardation, autosomal dominant 29 30.1 PBX1 ABL1
20 myeloma, multiple 30.0 TCF3 PTPN11 MYC KIT FLT3 CDKN2A
21 b-cell adult acute lymphocytic leukemia 30.0 PBX1 CD19 ANPEP ABL1
22 marginal zone b-cell lymphoma 30.0 PAX5 MME CD19 CCR6
23 burkitt lymphoma 30.0 PAX5 MYC MME IL7 DNTT CDKN2B
24 adult acute lymphocytic leukemia 29.8 TCF3 PBX1 PAX5 ETV6 CDKN2B CD19
25 diffuse large b-cell lymphoma 29.8 PEG10 PAX5 MYC MME CDKN2A CD19
26 central nervous system leukemia 29.8 MME KMT2A CD34 CD19 ANPEP ABL1
27 mantle cell lymphoma 29.7 PAX5 MYC MME KIT CDKN2B CDKN2A
28 acute promyelocytic leukemia 29.6 MYC KMT2A FLT3 ETV6 CDKN2B CD34
29 leukemia, chronic myeloid 29.5 PTPN11 MYC KMT2A KIT FLT3 ETV6
30 childhood leukemia 29.5 TCF3 PTPN11 PBX1 KMT2A ETV6 CDKN2B
31 acute leukemia 29.5 TCF3 PBX1 PAX5 KMT2A KIT IL7
32 precursor t-cell acute lymphoblastic leukemia 29.4 MYC KMT2A IL7 FLT3 ETV6 DNTT
33 myelodysplastic syndrome 28.8 PTPN11 MYC KMT2A KIT IL7 FLT3
34 childhood acute lymphocytic leukemia 28.8 PTPN11 PBX1 PAX5 MME KMT2A IL7
35 leukemia, chronic lymphocytic 28.6 PTPN11 PEG10 PAX5 MYC MME KMT2A
36 leukemia, acute myeloid 28.6 TCF3 PTPN11 PBX1 PAX5 MYC MME
37 b-lymphoblastic leukemia/lymphoma with etv6-runx1 11.8
38 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 11.8
39 b-lymphoblastic leukemia/lymphoma kmt2a rearranged 11.7
40 b-lymphoblastic leukemia/lymphoma with il3-igh 11.7
41 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.7
42 b-lymphoblastic leukemia/lymphoma with t 11.7
43 b-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) 11.6
44 b-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) 11.5
45 b-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) 11.5
46 b-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality 11.4
47 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 11.4
48 spinal cord sarcoma 10.5 KIT CD34
49 gallbladder leiomyoma 10.5 KIT CD34
50 spindle epithelial tumor with thymus-like differentiation tumor 10.5 KIT DNTT

Graphical network of the top 20 diseases related to B-Lymphoblastic Leukemia/lymphoma:



Diseases related to B-Lymphoblastic Leukemia/lymphoma

Symptoms & Phenotypes for B-Lymphoblastic Leukemia/lymphoma

GenomeRNAi Phenotypes related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.91 FLT3
2 Decreased viability GR00221-A-1 9.91 ABL1 CDKN2A FLT3 KIT MYC
3 Decreased viability GR00221-A-2 9.91 ABL1
4 Decreased viability GR00221-A-3 9.91 ABL1 CDKN2A MYC
5 Decreased viability GR00221-A-4 9.91 CDKN2A FLT3
6 Decreased viability GR00249-S 9.91 MYC
7 Decreased viability GR00301-A 9.91 KIT
8 Decreased viability GR00342-S-1 9.91 ABL1
9 Decreased viability GR00342-S-2 9.91 ABL1
10 Decreased viability GR00342-S-3 9.91 ABL1
11 Decreased viability GR00402-S-2 9.91 MYC
12 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
13 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
14 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
15 Reduced mammosphere formation GR00396-S 9.17 CCR6 CD34 ETV6 KMT2A MYC PTPN11

MGI Mouse Phenotypes related to B-Lymphoblastic Leukemia/lymphoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 ABL1 CD19 CD34 CDKN2A CDKN2B ETV6
2 hematopoietic system MP:0005397 10.46 ABL1 ANPEP CCR6 CD19 CD34 CDKN2A
3 immune system MP:0005387 10.45 ABL1 ANPEP CCR6 CD19 CD34 CDKN2A
4 homeostasis/metabolism MP:0005376 10.42 ABL1 CCR6 CD19 CD34 CDKN2A CDKN2B
5 growth/size/body region MP:0005378 10.37 ABL1 CD19 CDKN2A DNTT ETV6 FLT3
6 cardiovascular system MP:0005385 10.35 ABL1 ANPEP CD19 CDKN2A ETV6 KIT
7 endocrine/exocrine gland MP:0005379 10.31 ABL1 ANPEP CDKN2A CDKN2B ETV6 FLT3
8 embryo MP:0005380 10.25 ABL1 CDKN2A ETV6 KIT KMT2A MYC
9 mortality/aging MP:0010768 10.25 ABL1 CD19 CDKN2A CDKN2B ETV6 FLT3
10 integument MP:0010771 10.23 ANPEP CD19 CD34 CDKN2A CDKN2B ETV6
11 liver/biliary system MP:0005370 10.17 ABL1 CD19 CDKN2A ETV6 KIT KMT2A
12 digestive/alimentary MP:0005381 10.16 ABL1 CD19 CDKN2A ETV6 KIT MYC
13 neoplasm MP:0002006 10.1 CD19 CD34 CDKN2A CDKN2B ETV6 FLT3
14 nervous system MP:0003631 10.03 ABL1 CCR6 CD19 CDKN2A KIT KMT2A
15 muscle MP:0005369 9.97 ABL1 CDKN2A KIT KMT2A MYC PAX5
16 no phenotypic analysis MP:0003012 9.85 CDKN2A CDKN2B ETV6 FLT3 IL7 KIT
17 normal MP:0002873 9.73 ABL1 CCR6 CD19 DNTT ETV6 KIT
18 skeleton MP:0005390 9.32 ABL1 CDKN2A DNTT FLT3 KIT KMT2A

Drugs & Therapeutics for B-Lymphoblastic Leukemia/lymphoma

Drugs for B-Lymphoblastic Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4 174722-31-7 10201696
2
Etoposide Approved Phase 4 33419-42-0 36462
3
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8 Etoposide phosphate Phase 4
9
Isophosphamide mustard Phase 4 100427
10 Estradiol 17 beta-cypionate Phase 4
11 Estrogens Phase 4
12 Estradiol 3-benzoate Phase 4
13 Progestins Phase 4
14
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
15
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
16
Interferon beta-1b Approved Phase 3 145155-23-3
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
20
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
21
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
22
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
25
Sulfasalazine Approved Phase 3 599-79-1 5353980 5359476
26
Daunorubicin Approved Phase 3 20830-81-3 30323
27
Thioguanine Approved Phase 3 154-42-7 2723601
28
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
29
Ichthammol Approved Phase 3 8029-68-3
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
31
Blinatumomab Approved, Investigational Phase 3 853426-35-4
32
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
33
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
34
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
35
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
36
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
37
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
38
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
39
Cortisone Experimental Phase 3 53-06-5 222786
40 Imatinib Mesylate Phase 3 220127-57-1 123596
41 Antimitotic Agents Phase 3
42 Tubulin Modulators Phase 3
43 (T,G)-A-L Phase 3
44
Glatiramer Acetate Phase 3 147245-92-9 3081884
45 Adjuvants, Immunologic Phase 3
46 interferons Phase 3
47 Interferon-beta Phase 3
48 Antineoplastic Agents, Immunological Phase 3
49 Methylprednisolone Acetate Phase 3
50 Neuroprotective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone Completed NCT01940653 Phase 4 Progesterone
4 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
5 International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg Completed NCT00459667 Phase 3 Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046);Interferon beta-1b (Betaseron, BAY86-5046)
6 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
7 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
8 A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) Recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Pegaspargase;Prednisolone;Prednisone;Thioguanine;Vincristine Sulfate
9 SPondyloArthritis: Inducing Drug-free Remission by Early TNF-Alpha bloCkade Under Guidance of Single Cell RNA Sequencing and Epigenetic Profiling. "The SPARTACUS Trial" Recruiting NCT04435288 Phase 3 week 24;week 36;Week 48;Week 60
10 Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
11 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) Active, not recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine;Vincristine Sulfate
12 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
13 Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients Unknown status NCT03142646 Phase 1, Phase 2
14 Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study. Completed NCT01219816 Phase 2 Epratuzumab;Epratuzumab
15 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
16 Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy Completed NCT00324779 Phase 2
17 Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II Completed NCT00187161 Phase 2 Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
18 Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma Completed NCT01290120 Phase 2 Chemotherapy-Rituximab combination
19 Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients Completed NCT03173417 Phase 1, Phase 2 fludarabine and cyclophosphamide
20 Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL) Recruiting NCT04276870 Phase 2
21 Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open Label Phase I-II Clinical Trial of Automatically Produced Cell Therapy Product MB-CAR-T19-22 Using CliniMACS Prodigy Recruiting NCT04499573 Phase 1, Phase 2 CD19/CD22 CAR-T
22 A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old With First Relapse Recruiting NCT04546399 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
23 An Open-label, First-in-human, Dose Escalation Study of SAR440234 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), or High Risk Myelodysplasia (HR-MDS) Recruiting NCT03594955 Phase 1, Phase 2 SAR440234
24 Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT03792633 Phase 2
25 A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy Recruiting NCT03902197 Phase 2
26 A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy Recruiting NCT03876769 Phase 2
27 A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL). Recruiting NCT03743246 Phase 1, Phase 2 JCAR017;Lymphodepleting;Fludarabine;Cyclophosphamide
28 A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT03851081 Phase 1, Phase 2 Vincristine Sulfate Liposome
29 Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial) Active, not recruiting NCT04045743 Phase 2 MABp1 (Bermekimab) OR Placebo;MABp1 (Bermekimab)
30 Phase 1/2 Dose Escalation and Preliminary Efficacy of CD19 Directed Car T Cells Generated Using The Miltenyi Clinimacs Prodigy System (UCD19 CarT) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkins Lymphoma(B-NHL) Not yet recruiting NCT04544592 Phase 1, Phase 2 CD19CAR-CD3Zeta-4-1BB-Expressing Allogeneic T-Lymphocyte Cells
31 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Suspended NCT02981628 Phase 2 Cyclophosphamide;Cytarabine;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Vincristine
32 A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL) Terminated NCT02129062 Phase 2 Ibrutinib
33 A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Terminated NCT01685021 Phase 2 MOR00208 (formerly Xmab5574)
34 Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL Withdrawn NCT02844530 Phase 2 90Y-epratuzumab tetraxetan;chemotherapy/ immunotherapy
35 Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL) Unknown status NCT03574168 Phase 1
36 Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL) Unknown status NCT03671460 Phase 1
37 Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Male and Female Volunteers Completed NCT01744704 Phase 1 rhNGF 0.5 µg/mL Sentinel;rhNGF 5 µg/mL Sentinel;rhNGF 20 µg/mL Sentinel;rhNGF 20 µg/mL Part A;rhNGF 60 µg/mL Part A;rhNGF 180 µg/mL Part A;rhNGF 20 µg/mL Part B;rhNGF 60 µg/mL Part B;rhNGF 180 µg/mL Part B;Placebo Part A;Placebo Part B
38 Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL) Completed NCT02746952 Phase 1
39 A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours. Completed NCT02579226 Phase 1 AZD2811
40 Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies Recruiting NCT04088890 Phase 1 Fludarabine;Cyclophosphamide;CD22 CAR
41 A Phase 1 Study of ABL001 in Combination With Dasatinib and Prednisone in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML) Recruiting NCT03595917 Phase 1 ABL001;Dasatinib;Prednisone
42 Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Younger Adults Ages 18-55 With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT03962465 Phase 1 Inotuzumab ozogamicin;Prednisone Pill;Daunorubicin;Vincristine;Cytarabine;Methotrexate;Pegaspargase
43 Phase I, Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NCT04150497 Phase 1
44 A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Recruiting NCT04521231 Phase 1 Blinatumomab
45 A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Recruiting NCT04690595 Phase 1
46 BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Recovery From Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I) Recruiting NCT03396575 Phase 1 Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;Dose-Intensified TMZ;Td vaccine
47 ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I). Recruiting NCT03334305 Phase 1 Dose-intensified TMZ;Td vaccine
48 S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia) Active, not recruiting NCT01925131 Phase 1 cyclophosphamide;vincristine sulfate;prednisone
49 A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Active, not recruiting NCT01044069 Phase 1
50 Randomized, Parallel-arm, Controlled Trial of Senl_1904A and Senl_1904B Autologous CAR-T Cell Injections in the Treatment of Relapsed and Refractory Acute B Lymphocytic Leukemia(r/r B-ALL) Active, not recruiting NCT03840317 Phase 1

Search NIH Clinical Center for B-Lymphoblastic Leukemia/lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Lymphoblastic Leukemia/lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for B-Lymphoblastic Leukemia/lymphoma:
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to B-Lymphoblastic Leukemia/lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for B-Lymphoblastic Leukemia/lymphoma

Anatomical Context for B-Lymphoblastic Leukemia/lymphoma

MalaCards organs/tissues related to B-Lymphoblastic Leukemia/lymphoma:

40
T Cells, Bone Marrow, Myeloid, Breast, Heart, Prostate, Brain

Publications for B-Lymphoblastic Leukemia/lymphoma

Articles related to B-Lymphoblastic Leukemia/lymphoma:

(show top 50) (show all 7173)
# Title Authors PMID Year
1
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. 54 61
20160164 2010
2
[Prognostic significance of TEL/AML1 rearrangement and its additional genetic changes in Korean childhood precursor B-acute lymphoblastic leukemia]. 61 54
20197715 2010
3
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 61 54
20023257 2010
4
ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. 54 61
20082857 2010
5
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. 61 54
19837270 2009
6
[Characteristics of fusion gene and immunophenotype in MLL gene rearrangement positive childhood acute lymphoblastic leukemia]. 54 61
19840468 2009
7
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 54 61
18923441 2009
8
Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. 54 61
19143872 2009
9
[Gene expression profile of human TGF-beta signal transduction pathway of B cell type acute lymphocytic leukemia]. 54 61
18718051 2008
10
Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. 61 54
17434163 2007
11
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 61 54
17430665 2007
12
Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. 54 61
17652839 2007
13
CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. 54 61
17082584 2006
14
Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. 54 61
16938666 2006
15
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. 54 61
16939815 2006
16
Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. 54 61
16118018 2006
17
[Expression of the transcription factor PAX5 in childhood acute leukemic cells]. 61 54
16584581 2006
18
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). 61 54
16809887 2006
19
Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. 61 54
16234090 2005
20
[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. 54 61
16185473 2005
21
Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. 61 54
15801954 2005
22
PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia. 54 61
16225771 2004
23
[CXCR4 expression in B-lineage acute lymphocyte leukemia and its significance]. 54 61
15363127 2004
24
Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. 54 61
15098014 2004
25
Is B-lineage acute lymphoblastic leukemia with a mature phenotype and l1 morphology a precursor B-lymphoblastic leukemia/lymphoma or Burkitt leukemia/lymphoma? 54 61
14521459 2003
26
[Analysis of immunophenotype of B-lineage acute lymphoblastic leukemia cells by 4-color flow cytometry]. 61 54
12744734 2003
27
[Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia]. 61 54
12744735 2003
28
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias. 61 54
12870051 2003
29
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. 61 54
12393484 2003
30
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 54 61
11697497 2001
31
Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. 54 61
11337015 2001
32
Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. 54 61
11699224 2001
33
Differential expression of chemokine receptors in B cell malignancies. 61 54
11368435 2001
34
Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. 54 61
11237064 2001
35
Shifts in expression of immunological cell markers in relapsed acute leukemia. 54 61
11583283 2001
36
[Classification of acute leukemias according to the first latin-american consensus conference for the immunophenotyping of leukemias]. 61 54
11195181 2000
37
Expression of adhesion molecules in childhood B-lineage-cell neoplasms. 54 61
10979212 2000
38
Acute lymphoblastic leukaemia: correlation between morphological/immunohistochemical and molecular biological findings in bone marrow biopsy specimens. 54 61
10889907 2000
39
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. 61 54
10634644 2000
40
[Homozygous deletion and methylation of p16 and p15 gene in acute leukemia]. 61 54
11721412 1999
41
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. 54 61
10419905 1999
42
p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. 61 54
10360377 1999
43
Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. 61 54
10233379 1999
44
Myeloperoxidase gene expression in infant leukemia: a Pediatric Oncology Group Study. 61 54
9638984 1998
45
Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. 61 54
9477130 1997
46
Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. 54 61
9399648 1997
47
C-kit receptors in childhood malignant lymphoblastic cells. 54 61
9168431 1997
48
Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. 54 61
9187426 1997
49
Coexpression of cell-surface immunoglobulin (sIg), terminal deoxynucleotidyl transferase (TdT) and recombination activating gene 1 (RAG-1): two cases and derived cell lines. 54 61
8683996 1996
50
Heterogeneity of B lineage acute lymphoblastic leukemias (B-ALL) with regard to their in vitro spontaneous proliferation, growth factor response and BCL-2 expression. 54 61
8726408 1996

Variations for B-Lymphoblastic Leukemia/lymphoma

ClinVar genetic disease variations for B-Lymphoblastic Leukemia/lymphoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CDH1 NM_004360.5(CDH1):c.1865A>G (p.Asn622Ser) SNV Uncertain significance 136062 rs147925149 16:68856057-68856057 16:68822154-68822154

Expression for B-Lymphoblastic Leukemia/lymphoma

Search GEO for disease gene expression data for B-Lymphoblastic Leukemia/lymphoma.

Pathways for B-Lymphoblastic Leukemia/lymphoma

Pathways related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 PTPN11 MYC MME KIT IL7 FLT3
2
Show member pathways
13.7 TCF3 MYC KIT IL7 FLT3 CDKN2B
3
Show member pathways
12.72 PTPN11 MYC KIT FLT3 CDKN2A ABL1
4 12.64 MYC KIT IL7 FLT3 CDKN2B CDKN2A
5 12.4 TCF3 PBX1 PAX5 KIT CD34 CD19
6 12.22 MYC CDKN2B CDKN2A ABL1
7 12.18 TCF3 MYC CDKN2B CDKN2A
8 11.98 TCF3 PBX1 PAX5 MYC KMT2A FLT3
9 11.75 KIT CD34 CD19
10 11.64 KIT IL7 CD34 CCR6
11 11.63 TCF3 MYC CDKN2B
12 11.61 PAX5 MYC KIT CD34 ANPEP
13 11.57 MYC KIT FLT3
14 11.56 MME KIT IL7 FLT3 CD34 CD19
15 11.52 MME KIT FLT3 CD34 CD19
16 11.49 MYC DNTT CDKN2B
17 11.42 PTPN11 MYC ABL1
18 11.22 MME KIT IL7 FLT3 DNTT CD34
19
Show member pathways
11 MYC CDKN2A ABL1
20 10.98 MYC CDKN2A ABL1

GO Terms for B-Lymphoblastic Leukemia/lymphoma

Cellular components related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.35 KIT CD34 CD19 CCR6 ANPEP
2 protein-containing complex GO:0032991 9.17 TCF3 PTPN11 MYC FLT3 CDKN2A CD19

Biological processes related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10 PBX1 MYC KIT IL7 FLT3
2 positive regulation of gene expression GO:0010628 9.98 MYC KIT IL7 CDKN2A CD34
3 cell differentiation GO:0030154 9.95 TCF3 PEG10 PBX1 PAX5 FLT3 ETV6
4 B cell differentiation GO:0030183 9.75 TCF3 KIT FLT3
5 cytokine-mediated signaling pathway GO:0019221 9.72 PTPN11 MYC KIT IL7 FLT3
6 regulation of hematopoietic stem cell differentiation GO:1902036 9.7 TCF3 KMT2A ABL1
7 hemopoiesis GO:0030097 9.69 KIT FLT3 CD34
8 cellular response to cytokine stimulus GO:0071345 9.67 PTPN11 MME FLT3
9 cell cycle arrest GO:0007050 9.67 MYC CDKN2B CDKN2A ABL1
10 humoral immune response GO:0006959 9.65 PAX5 IL7 CCR6
11 regulation of B cell receptor signaling pathway GO:0050855 9.59 PAX5 CD19
12 Bergmann glial cell differentiation GO:0060020 9.57 PTPN11 ABL1
13 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.56 CDKN2A ABL1
14 somatic stem cell division GO:0048103 9.55 KIT CDKN2A
15 regulation of protein export from nucleus GO:0046825 9.54 PTPN11 CDKN2A
16 B cell proliferation involved in immune response GO:0002322 9.46 CD19 ABL1
17 myeloid progenitor cell differentiation GO:0002318 9.43 KIT FLT3
18 spleen development GO:0048536 9.43 PBX1 CDKN2B ABL1
19 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.33 KIT FLT3 CD19
20 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 TCF3 PBX1 PAX5 MYC KMT2A ETV6
21 embryonic hemopoiesis GO:0035162 9.13 PBX1 KMT2A KIT

Molecular functions related to B-Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 TCF3 PTPN11 PEG10 PBX1 PAX5 MYC
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 TCF3 PBX1 PAX5 MYC ETV6
3 transcription factor binding GO:0008134 9.35 TCF3 PBX1 MYC CDKN2A CD34
4 DNA binding GO:0003677 9.32 TCF3 PEG10 PBX1 PAX5 MYC KMT2A
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2B CDKN2A

Sources for B-Lymphoblastic Leukemia/lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....